Pulse Biosciences CCO Executes Strategic 10b5‑1 Trades, Adding 40,000 Shares Amid Clinical Success Flash News
Pulse Biosciences insider trading shows CEO Danahy’s disciplined confidence, buying near 52‑week highs while managing liquidity, signaling a potential commercial upswing.
4 minutes to read